Matching trials
18 results
- ARTS-HFIndependent statistical analysis of the ARTS-HF phase 2 trial of finerenone in worsening chronic heart failure with left ventricular systolic dysfunction and selected diabetes or chronic kidney disease populations.
- BOLERO-6Independent statistical analysis of the BOLERO-6 phase 2 trial of everolimus plus exemestane versus everolimus alone and capecitabine in advanced breast cancer, including time-to-event methods, non-inferiority interpretation, quality-of-life analyses, and safety.
- CAPRISA 008Independent statistical analysis of CAPRISA 008, a randomized phase 2/3 trial evaluating 1% tenofovir gel provision through family planning services for HIV prevention, including adherence, HIV incidence, pregnancy, HPV, and safety analyses.
- CAPTIVATEIndependent statistical analysis of CAPTIVATE (NCT02910583), a randomized phase 2 trial of ibrutinib plus venetoclax in treatment-naive chronic lymphocytic leukemia and small lymphocytic lymphoma, including its primary endpoints, statistical methods, and interpretation.
- COMET-PEAKIndependent statistical analysis of COMET-PEAK, the randomized phase 2 trial evaluating second-generation sotrovimab material in non-hospitalized participants with mild to moderate COVID-19, including viral-load, pharmacokinetic, ANCOVA, ANOVA, safety, and statistical interpretation.
- EPIC-HRIndependent statistical analysis of the EPIC-HR randomized phase 2/3 trial of PF-07321332/ritonavir versus placebo in nonhospitalized high-risk adults with COVID-19, including endpoint definitions, statistical methods, reported results, safety, and interpretation.
- GEMINI-ACS-1Independent statistical analysis of GEMINI-ACS-1, a randomized phase 2 trial comparing rivaroxaban with acetylsalicylic acid in addition to P2Y12 inhibitor therapy in participants with acute coronary syndrome.
- HPTN 083Independent statistical analysis of HPTN 083, a randomized phase 2/3 trial comparing injectable cabotegravir with TDF/FTC for HIV pre-exposure prophylaxis in HIV-uninfected men and transgender women who have sex with men.
- HVTN 505Complete statistical analysis of HVTN 505, a randomized phase 2 trial of HIV-1 DNA plasmid and recombinant adenoviral vector vaccines in HIV-uninfected participants, including trial design, endpoints, Cox survival analyses, safety, and…
- HVTN 702Independent statistical analysis of HVTN 702, a randomized phase 2/3 HIV vaccine prevention trial evaluating ALVAC-HIV and bivalent subtype C gp120/MF59 versus placebo, including time-to-event methods, hazard ratios, confidence intervals, safety, and…
- INAVO120Independent statistical analysis of the INAVO120 trial of inavolisib plus palbociclib and fulvestrant versus placebo plus palbociclib and fulvestrant in PIK3CA-mutant, hormone receptor-positive, HER2-negative locally advanced or metastatic breast cancer.
- KEYNOTE-010Independent statistical analysis of KEYNOTE-010, including its randomized phase 2/3 design, overall survival, progression-free survival, response, safety, statistical methods, and interpretation.
- LUX-Lung 7Independent statistical analysis of LUX-Lung 7, the randomized phase 2 trial comparing afatinib with gefitinib in first-line EGFR mutation-positive lung adenocarcinoma, including survival, response, quality-of-life, and safety analyses.
- OPUSIndependent statistical analysis of the OPUS trial of cetuximab plus FOLFOX-4 versus FOLFOX-4 alone as first-line treatment for metastatic colorectal cancer, including response, progression-free survival, overall survival, KRAS subgroup analyses, methodology, and…
- RELATIVITY-047Independent statistical analysis of RELATIVITY-047, evaluating relatlimab plus nivolumab versus nivolumab alone in participants with advanced melanoma, including trial design, progression-free survival, statistical methodology, interpretation, and limitations.
- SKYSCRAPER-06Independent statistical analysis of SKYSCRAPER-06, evaluating tiragolumab plus atezolizumab and chemotherapy versus pembrolizumab plus chemotherapy in previously untreated advanced non-squamous NSCLC, with detailed interpretation of PFS, OS, response, quality-of-life, and safety analyses.
- TDF2Independent statistical analysis of the randomized TDF2 trial of tenofovir disoproxil fumarate plus emtricitabine for HIV prevention, including trial design, registered endpoints, Cox and logistic regression methods, reported results, safety, limitations, and…
- VOICEIndependent statistical analysis of the VOICE phase 2 trial of tenofovir 1% gel, oral tenofovir disoproxil fumarate, and emtricitabine/tenofovir disoproxil fumarate for prevention of HIV infection in women.